Epizyme, Inc
EPZM
EPZM was delisted on the 11th of August, 2022.
104 hedge funds and large institutions have $628M invested in Epizyme, Inc in 2018 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 35 increasing their positions, 29 reducing their positions, and 20 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 29
5% less funds holding
Funds holding: 109 → 104 (-5)
15% less call options, than puts
Call options by funds: $475K | Put options by funds: $560K
23% less capital invested
Capital invested by funds: $812M → $628M (-$184M)
25% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 20
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VOYA Investment Management
Atlanta,
Georgia
|
+$6.89M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.52M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$3.69M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$3.63M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$3.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$27.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$8.21M |
| 3 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
-$6.11M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$1.87M |
| 5 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$1.12M |
EPZM Hedge Fund Activity: Q3 2018 in Review
104 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q3 2018, worth a combined $628M — down 23% from $812M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of EPZM and 15 opened new positions — a net loss of 5 holders — while 29 trimmed existing stakes and 35 added.
The largest buyer was VOYA Investment Management, adding an estimated $6.89M. The largest seller was Fidelity Investments, cutting an estimated $27.7M.
- 104 institutional investors held Epizyme, Inc (EPZM) as of Q3 2018, down from 109 in Q2 2018.
- Funds reported $628M of Epizyme, Inc stock for Q3 2018, down 23% quarter-over-quarter.
- 15 funds opened new Epizyme, Inc positions in Q3 2018 and 20 closed out, a net change of -5 holders.
- The largest Epizyme, Inc buyer in Q3 2018 was VOYA Investment Management, an estimated $6.89M added.
- The largest Epizyme, Inc seller in Q3 2018 was Fidelity Investments, an estimated $27.7M sold.
Based on aggregated 13F filings for Q3 2018.